(Press-News.org) [Singapore -- 10:35 a.m. SGT--September 10, 2023] — The oral, selective KRAS G12C inhibitor The oral, selective KRAS G12C inhibitor KRAS-G12C inhibitor adagrasib demonstrated durable clinical activity, with a median overall survival of 14.1 months and approximately one in three patients alive at two years, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.
KRAS-G12C mutations occur in approximately 14% of patients with NSCLC. The KRYSTAL-1 study, a multi-cohort Phase 1/2 trial, evaluated adagrasib as a monotherapy or in combination for patients with KRAS-G12C-mutated solid tumors. The U.S. Food and Drug Administration (FDA) already granted accelerated approval of adagrasib for patients with previously treated KRAS-G12C-mutated advanced/metastatic NSCLC based on data from this study. Additionally, the European Medicines Agency (EMA) and the Medicines and Healthcare Products Regulatory Agency (MHRA) are currently reviewing the drug.
In the two-year follow-up, pooled analysis of the Phase 1/1b Cohort and Phase 2 Cohort A, 132 patients with KRAS-G12C-mutated NSCLC were treated with adagrasib 600 mg orally twice daily. The median age of patients was 64 years, with 56.8% being female. At baseline, 19.7% of patients had central nervous system metastases. Patients had received a median of two prior therapies, including platinum-based and checkpoint inhibitor therapies.
According to Shirish Gadgeel, MD from Henry Ford Cancer Institute, Henry Ford Health System, in Detroit, Mich., the results showed a favorable objective response rate (ORR) of 43.0%, with a median duration of response (DOR) of 12.4 months. The median progression-free survival (PFS) was 6.9 months, and the median overall survival (OS) was 14.1 months. Notably, 52.8% of patients were still alive at one year, and approximately one in three patients (31.3%) remained alive at two years. The findings suggest durable clinical activity of adagrasib for KRAS-G12C-mutated NSCLC.
“The study data demonstrates promising results, providing hope for patients with this specific mutation,” Dr. Gadgeel said. “Exploratory analyses indicated that the presence of co-mutations, such as KEAP1, STK11, or TP53, may impact the clinical benefit of adagrasib and warrant further investigation.”
Dr. Gadgeel reported that treatment-related adverse events were manageable, with grade ≥3 TRAEs occurring in 40.9% of patients. Only 2.3% of patients experienced grade 5 TRAEs, including pneumonitis, cardiac failure, and pulmonary hemorrhage.
The ongoing Phase 3 trial evaluating adagrasib monotherapy compared with docetaxel in previously treated advanced KRAS-G12C-mutated NSCLC holds great promise and could further establish adagrasib as an essential treatment option for patients with this specific mutation, he reported.
About the IASLC:
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 8,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit http://www.iaslc.org for more information.
About the WCLC:
The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting more than 7,000 researchers, physicians, and specialists from more than 100 countries. The goal is to increase awareness, collaboration, and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit https://wclc2023.iaslc.org.
END
KRYSTAL-1 trial finds that adagrasib demonstrates durable clinical activity in patients with KRAS-G12C mutations
2023-09-10
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Stigmatization of smoking-related diseases is a barrier to care and the problem may be on the rise
2023-09-10
[Singapore -- 10:35 a.m. SGT--September 10, 2023) –The stigma that patients face when diagnosed with lung cancer is associated with poorer psychosocial outcomes, including distress and isolation, delayed help-seeking, and concerns about the quality of care, according to research presented today at the International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer in Singapore.
The study, conducted by a team of researchers led by Nathan Harrison, a behavioral scientist and PhD student ...
Color of phlegm can predict outcomes for patients with the lung disease, bronchiectasis
2023-09-10
Milan, Italy: The colour of the phlegm from patients with the lung disease bronchiectasis can indicate the degree of inflammation in their lungs and predict their future outcomes, according to new research presented at the European Respiratory Society International Congress in Milan, Italy [1].
The study of nearly 20,000 patients from 31 countries is the first time that the colour of phlegm (also known as sputum) has been shown to provide clinically relevant information that reflects prognoses and, therefore, can aid decisions about ...
Scientists set sights on protein that controls skeletal muscle composition
2023-09-09
Tokyo, Japan – Researchers from Tokyo Metropolitan University have shown that the protein Musashi-2 (Msi2) plays a key role in the regulation of mass and metabolic processes in skeletal muscle. They studied mice with the Msi2 gene knocked out and found reduced muscle mass due to fewer type 2a muscle fibers. Myoglobin and mitochondria were also reduced. Type 2a fibers respond sensitively to training and illnesses; insights into their regulation will prove valuable in new therapies.
Skeletal muscle fibers are truly fascinating in how responsive they are. With training, we can significantly improve muscle mass, strength and endurance. On the other hand, with age or extended ...
More cases of breast cancer detected with the help of AI
2023-09-09
One radiologist supported by AI detected more cases of breast cancer in screening mammography than two radiologists working together, reports the ScreenTrustCAD study from Karolinska Institutet in The Lancet Digital Health. The researchers say that AI is now ready to be implemented in breast cancer screening.
For over 30 years, screening mammography has been an important key in reducing breast cancer mortality rates. However, challenges include a lack of radiologists and that not all cancers are detected. Several retrospective studies have shown that artificial ...
Mayo Clinic study reveals proton beam therapy may shorten breast cancer treatment
2023-09-09
ROCHESTER, Minn. — In a randomized trial, published in The Lancet Oncology, Mayo Clinic Comprehensive Cancer Center researchers uncover evidence supporting a shorter treatment time for breast cancer patients. The study compared two separate dosing schedules of pencil-beam scanning proton therapy, the most advanced type of proton therapy known for its precision in targeting cancer cells while preserving healthy tissue to reduce the risk of side effects.
Survival rates for breast cancer continue to improve due to advances in diagnosis and treatment, leading to increasing emphasis on reducing the long-term ...
Study reveals human destruction of global floodplains
2023-09-09
A University of Texas at Arlington hydrologist’s study in the Nature journal Scientific Data provides the first-ever global estimate of human destruction of natural floodplains. The study can help guide future development in a way that can restore and conserve vital floodplain habitats that are critical to wildlife, water quality and reducing flood risk for people.
Adnan Rajib, a UT Arlington assistant professor in the Department of Civil Engineering, was the lead author on the published study, “Human Alterations of the Global Floodplains.” His doctoral student, Qianjin Zheng, played a significant ...
MSU research shows table salt could be the secret ingredient for better chemical recycling
2023-09-08
Images
Researchers at Michigan State University have shown that table salt outperforms other expensive catalysts being explored for the chemical recycling of polyolefin polymers, which account for 60% of plastic waste.
The research, published in the journal Advanced Sustainable Systems, shows that sodium chloride could provide a safe, inexpensive and reusable way to make plastics more recyclable.
The team also showed that table salt and other catalysts could be used in the recycling of metallized plastic films — like ...
RESEARCH ALERT: City of Hope scientists identify new therapeutic target for metastatic cancer
2023-09-08
FINDINGS
In a recent study led by Lei Jiang, Ph.D., an assistant professor of molecular and cellular endocrinology, a team of researchers from City of Hope and the University of Texas Southwestern Medical Center, found a potential new target for treating patients with metastatic cancer. Their findings were published in the August 29 issue of the journal Cell Reports.
The goal of the team’s study was to elucidate the role of reductive carboxylation in redox metabolism, a process believed to be important for metastatic cancer. Reductive carboxylation is best known as a metabolic pathway that provides a molecule called acetyl-CoA so that it can be turned into lipids, which ...
McWilliams School of Biomedical Informatics researchers awarded $3.4M NIH grant to understand link between chronic health conditions and Alzheimer's disease
2023-09-08
A three-year, $3.4 million grant to investigate how Alzheimer’s disease is connected to multiple chronic diseases has been awarded to UTHealth Houston researchers by the National Institute on Aging, part of the National Institutes of Health.
To study this, a team led by Xiaoqian Jiang, PhD, principal investigator and professor and chair in the Department of Health Data Science and Artificial Intelligence with McWilliams School of Biomedical Informatics at UTHealth Houston, will build risk trajectory maps for patients using clinical data and electronic health records. Specifically, they will develop electronic health records ...
SwiftPharma and the Population Council pursue agreement to manufacture Griffithsin needed for the development of a fast-dissolving insert for protection against HIV
2023-09-08
September 8, 2023 – SwiftPharma, a Belgium-based manufacturer, and the Population Council, a global nonprofit research organization, have signed a Manufacturing Master Service Agreement for the plant-based manufacture of Griffithsin to further the Council’s development of a Griffithsin fast-dissolving vaginal insert for protection against HIV.
The Population Council has been developing a non-antiretroviral HIV-prevention method containing Griffithsin (GRFT) in a fast-dissolving insert (FDI). This Griffithsin FDI is an on-demand, user-controlled, portable prevention technology in early development ...